SK-LMS-1 Cells

SK-LMS-1 is a human leiomyosarcoma cell line that has been widely used for cancer research, particularly for studies investigating therapeutic agents targeting soft tissue sarcomas. Leiomyosarcoma is a type of malignant tumor that arises from smooth muscle tissues, and the SK-LMS-1 cell line models this disease effectively in vitro. These cells express the c-Met proto-oncogene, which plays a critical role in tumorigenesis, proliferation, and metastasis in many cancers, including leiomyosarcoma. The aberrant expression of c-Met in SK-LMS-1 makes it a valuable model for studying c-Met-targeted therapies. One significant study involved the identification of a Met-binding peptide, Met-pep1, through phage display library screening. This peptide demonstrated specificity for the Met receptor and was capable of competing with hepatocyte growth factor (HGF) for receptor binding, inhibiting tumor cell proliferation. SK-LMS-1 cells treated with Met-pep1 showed decreased proliferation, suggesting that targeting c-Met with this peptide could have therapeutic potential. The internalization of the peptide by SK-LMS-1 cells after binding to c-Met further supports its potential as a diagnostic or therapeutic agent, particularly in nuclear imaging studies where tumor-associated activity was successfully visualized in vivo using SK-LMS-1 xenografts. Additionally, SK-LMS-1 cells have been used to explore the effects of natural compounds such as Flavokawain B (FKB), a chalcone derived from the kava plant. FKB was found to induce G2/M cell cycle arrest and robust apoptosis in SK-LMS-1 cells, mediated by the upregulation of pro-apoptotic proteins like DR5, Bim, and Puma, and downregulation of the anti-apoptotic protein survivin. The combination of FKB with chemotherapeutic agents such as docetaxel and gemcitabine exhibited a synergistic effect, further inhibiting the growth of SK-LMS-1 cells.